Next Article in Journal
Green Silver Nanoparticles: An Antibacterial Mechanism
Previous Article in Journal
Standardization of the Agar Plate Method for Bacteriophage Production
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874

by
Cristina Kirkegaard-Biosca
1,2,
Ester del Barrio-Tofiño
3,
Miguel Villamarín
1,
Nieves Larrosa
2,3,4,
David Campany
5,
Juan José González-López
2,3,4,
Ricard Ferrer
2,6,7,
Belén Viñado
3,
Laura Doménech
5,
Julia Sellarès-Nadal
1,2,
Laura Escolà-Vergé
2,4,8,
Nuria Fernández-Hidalgo
1,2,4,* and
Ibai Los-Arcos
1,2,4,*
1
Infectious Diseases Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
2
Department of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
3
Microbiology Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
4
CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain
5
Pharmacy Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
6
Critical Care Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
7
Sepsis Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d’Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain
8
Infectious Diseases Unit, Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Antibiotics 2025, 14(1), 4; https://doi.org/10.3390/antibiotics14010004
Submission received: 28 November 2024 / Accepted: 13 December 2024 / Published: 24 December 2024
Error in Table 2
In the original publication [1], there was a mistake in Table 2, published as follows: Patients 1 and 23 presented clinical failure at day 14, as reported in the text. In addition, by error patient 23 should also appear as mortality at day 30: Yes, and patient 24 mortality at day 30 should be No.
The corrected version of Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Table 2. Demographic, clinical, and outcome characteristics of the 34 patients with infections caused by VIM-type-producing Gram-negative bacteria treated with cefiderocol.
Table 2. Demographic, clinical, and outcome characteristics of the 34 patients with infections caused by VIM-type-producing Gram-negative bacteria treated with cefiderocol.
PatientAge, yr (Sex)Underlying DiseaseCCIType of InfectionBacterial SpeciesBacteremiaDrainable Source/Drainage PerformedAdditional TherapyDays of TreatmentClinical Failure at Day 14Mortality at Day 30
182 (M)Renal transplant recipient7Primary bacteremiaP. aeruginosaYesNoNo8YesYes
289 (M)Chronic ischemia right lower limb14Chronic osteomyelitisE. cloacaeNoYes/Yes: Limb amputationNo13NoYes
363 (M)Lung transplant recipient2Previous ECMO cannula wound infectionRaoultella ornithinolytica,
E. coli
NoYes/Yes: Resection of the infected woundNo13NoNo
476 (F)Diverticulitis4Postoperative deep wound infectionAchromobacter sp., P. aeruginosaNoYes/No: Undrained abscessNo8NoNo
556 (M)COVID-19 pneumonia3Primary bacteremia and ECMO cannula infectionAchromobacter sp.YesYes/No: ECMO cannula not retiredIntravenous colistin (after 22 days of cefiderocol)27YesYes
639 (M)COVID-19 pneumonia in a lung transplant recipient1ECMO cannula wound infection + tracheobronchitisP. aeruginosaNoYes/No: ECMO cannula not retiredNebulized colistin6YesYes
751 (M)Acute pancreatitis2Catheter-associated urinary infectionAchromobacter sp.NoNoNo11NoYes
878 (F)Renal transplant recipient10Femoro-femoral bypass graft infectionE. cloacaeNoYes/No: By-pass not explantedNo13NoNo
965 (M)Renal transplant recipient6Obstructive pyelonephritisE. cloacae,
P. aeruginosa
YesYes/Yes: Ureteral stent placementNo27NoNo
1059 (M)Acute myeloid leukemia and recent allo-HSCT3Tonsillar abscessP. aeruginosaYesYes/No: Undrained abscessIntravenous amikacin (during the first 3 days)22YesYes
1141 (M)NK/T-cell lymphoma2Infected pancreatic necrosisP. aeruginosaNoYes/Yes: Abscess drainageNo62NoNo
1256 (F)Follicular lymphoma with persistent COVID-192Catheter-associated UTIAchromobacter sp.NoNoNo5NoNo
1367 (M)Lung transplant recipient2Acute tracheobronchitisP. aeruginosaNoNoNebulized colistin7NoNo
1477 (F)Acute myeloid leukemia5Soft tissue infectionP. aeruginosaNoNoNo14NoNo
1561 (M)Hemorrhagic shock7Catheter-associated UTIAchromobacter sp.NoNoNo7NoYes
1656 (M)Tibial osteomyelitis0Chronic osteomyelitisP. putidaNoYes/Yes: Osteomyelitis debridement No14NoNo
1770 (M)COPD5Nosocomial pneumoniaP. aeruginosaYesNoNo25NoYes
1851 (M)Renal transplant recipient3Renal graft pyelonephritisP. aeruginosaNoNoNo17NoNo
1954 (M)Elbow osteomyelitis1Osteosynthesis-associated infectionE. cloacaeNoYes/Yes: Osteosynthesis implant removalNo32NoNo
2058 (M)Renal transplant recipient4Postoperative deep wound infectionP. aeruginosaNoYes/No: Undrained abscessNo28NoNo
2167 (M)Lung transplant recipient4Acute tracheobronchitisP. aeruginosaYesNoNebulized colistin15NoNo
2254 (F)Lung transplant recipient3Acute tracheobronchitisEnterobacter hormaecheiNoNoNebulized amikacin6NoNo
2345 (M)Richter’s Syndrome2Intestinal bacterial translocationP. aeruginosaYesNoNo9YesYes
2453 (F)Open tibia fracture1Tibial osteomyelitisP. aeruginosaNoYes/Yes: Osteomyelitis debridementNo38NoNo
2554 (F)Metastatic kidney cancer5Catheter-related bloodstream infectionP. aeruginosaYesYes/Yes: Catheter removalNo5NoNo
2678 (F)Renal transplant recipient9Postoperative deep wound infectionP. putidaNoYes/Yes: Abscess drainageNo41NoNo
2744 (F)Renal transplant recipient3Postoperative deep wound infectionP. putidaNoYes/No: Undrained abscessNo12NoNo
2849 (M)Lung transplant recipient4Acute tracheobronchitisP. aeruginosaNoNoNo14NoNo
2975 (M)Status epilepticus3Ventilator-associated pneumoniaP. aeruginosaNoNoNebulized colistin9NoNo
3077 (M)Multiple organ dysfunction syndrome8Acute tracheobronchitisP. aeruginosaNoNoNo10NoNo
3159 (F)Pulmonary fibrosis1Acute tracheobronchitisP. aeruginosaNoNoNebulized colistin8NoNo
3280 (M)Meige syndrome (tracheostomy)4Acute tracheobronchitisP. aeruginosaNoNoNebulized aztreonam10NoNo
3356 (M)Acute lymphoblastic leukemia4Prostatic abscessP. aeruginosaNoYes/No: Undrained abscessNo33NoNo
3463 (M)Renal transplant recipient5Renal graft pyelonephritisP. putidaNoNoNo18NoNo
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; CCI, Charlson comorbidity index; ECMO, extracorporeal membrane oxygenation; F, female; M, male; UTI, urinary tract infection; and COPD, chronic obstructive pulmonary disease.

Reference

  1. Kirkegaard-Biosca, C.; del Barrio-Tofiño, E.; Villamarín, M.; Larrosa, N.; Campany, D.; González-López, J.J.; Ferrer, R.; Viñado, B.; Doménech, L.; Sellarès-Nadal, J.; et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kirkegaard-Biosca, C.; del Barrio-Tofiño, E.; Villamarín, M.; Larrosa, N.; Campany, D.; González-López, J.J.; Ferrer, R.; Viñado, B.; Doménech, L.; Sellarès-Nadal, J.; et al. Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. Antibiotics 2025, 14, 4. https://doi.org/10.3390/antibiotics14010004

AMA Style

Kirkegaard-Biosca C, del Barrio-Tofiño E, Villamarín M, Larrosa N, Campany D, González-López JJ, Ferrer R, Viñado B, Doménech L, Sellarès-Nadal J, et al. Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. Antibiotics. 2025; 14(1):4. https://doi.org/10.3390/antibiotics14010004

Chicago/Turabian Style

Kirkegaard-Biosca, Cristina, Ester del Barrio-Tofiño, Miguel Villamarín, Nieves Larrosa, David Campany, Juan José González-López, Ricard Ferrer, Belén Viñado, Laura Doménech, Julia Sellarès-Nadal, and et al. 2025. "Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874" Antibiotics 14, no. 1: 4. https://doi.org/10.3390/antibiotics14010004

APA Style

Kirkegaard-Biosca, C., del Barrio-Tofiño, E., Villamarín, M., Larrosa, N., Campany, D., González-López, J. J., Ferrer, R., Viñado, B., Doménech, L., Sellarès-Nadal, J., Escolà-Vergé, L., Fernández-Hidalgo, N., & Los-Arcos, I. (2025). Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874. Antibiotics, 14(1), 4. https://doi.org/10.3390/antibiotics14010004

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop